đź“‹ FDA Reference
ezvue ocufilcon d 1-day soft hydrophilic contact lens
I-See Vision Technology
Summary: The ezvue ocufilcon d 1-day soft hydrophilic contact lens is a daily disposable contact lens designed for vision correction. It is primarily used by optometrists and ophthalmologists for patients requiring vision correction without the need for glasses.
FDA Clearance Information
Pathway
510K
Number
K082880 ↗
Decision Date
June 16, 2009
Product Code
LPL
Device Class
Class 2
Evidence
419 studies
The ezvue ocufilcon d 1-day contact lens was cleared through the FDA's 510k pathway on June 16, 2009. Manufactured by I-See Vision Technology, it is classified as a Class 2 medical device.
What It Is
The ezvue ocufilcon d 1-day soft hydrophilic contact lens is a daily disposable lens made from ocufilcon D, a hydrogel material that retains moisture for comfort. It is designed to correct refractive errors such as myopia and hyperopia. The lens is intended for single-day use, providing convenience and reducing the risk of infection associated with extended wear.
Clinical Applications
These contact lenses are commonly used in optometry and ophthalmology clinics for patients seeking an alternative to glasses. They are suitable for individuals with active lifestyles or those who prefer not to wear glasses. The lenses are also ideal for patients with mild to moderate refractive errors and can be used in various settings, including sports and outdoor activities.
Indications for Use
The FDA indications for the ezvue ocufilcon d 1-day contact lens include vision correction for patients with myopia (nearsightedness) or hyperopia (farsightedness). It is intended for daily wear and should be discarded after each use.
Practical Considerations
The ezvue ocufilcon d lenses are available in a range of powers to accommodate different levels of vision correction. They are designed for easy handling and insertion, making them suitable for both new and experienced contact lens wearers. It is important to follow proper hygiene practices to ensure safety and comfort.
Linked Studies (20)
PubMed • 2025
Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.
Journal of neuroendovascular therapy
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Performance evaluation of quantitative hemoglobin A2 and fetal hemoglobin testing using commercially lyophilized vs. in-house whole blood controls in Chinese clinical laboratories: a 12-year analysis of National External Quality Assessment Data.
Clinical chemistry and laboratory medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical progress note: Haemophilus influenzae type b.
Journal of hospital medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Pilot study of social media promotion of home-based self-testing for syphilis.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical development and performance of the First to Know Syphilis Self-Test for over-the-counter usage: a de novo rapid test for treponemal antibody.
Journal of clinical microbiology
View Source →
PubMed • 2025
Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Evaluation of Rapid Syphilis Testing Using the Syphilis Health Check in Florida, 2015-2016.
Florida public health review
View Source →
PubMed • 2025
Multiplex droplet digital PCR for the detection and quantitation of Streptococcus pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae.
Frontiers in cellular and infection microbiology
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a.
Transboundary and emerging diseases
View Source →
PubMed • 2025
Tp40: a new potential prognostic and diagnostic marker for syphilis.
Microbiology spectrum
View Source →
PubMed • 2025
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver.
The Journal of clinical investigation
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Application value of Philips Ingenuity TF PET/CT scanner imaging agent FAP in evaluating renal fibrosis.
Hellenic journal of nuclear medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Message from Dr. Philippe T. Georgel, Guest Editor for the Marshall University Collection, Brad D. Smith, President of Marshall University, and Dr. Anivandan Mukherjee, Provost of Marshall University.
Biochemistry and cell biology = Biochimie et biologie cellulaire
View Source →
PubMed • 2025
Improved patient comfort and procedural efficiency using chlorhexidine-coated hydrophilic urethral catheters: a randomized controlled trial.
Journal of Yeungnam medical science
RCT View Source →
PubMed • 2025
pTx-Pulseq in hybrid sequences: Accessible and advanced hybrid open-source MRI sequences on Philips scanners.
Magnetic resonance in medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Comparative connectomics of Drosophila descending and ascending neurons.
Nature
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Hydrophilic-coated sheaths for reducing radial artery spasm during transradial procedures: A systematic review and meta-analysis.
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
View Source →
PubMed • 2025
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Zeitschrift fur Rheumatologie
View Source →
PubMed • 2025
A Hydrophilic Polyurethane Foam Containing Nigella sativa Oil as a Wound Dressing.
BioMed research international
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What is ezvue ocufilcon d 1-day contact lens used for?
It is used for correcting refractive errors such as myopia and hyperopia, providing an alternative to glasses.
What specialties typically use this device?
Optometrists and ophthalmologists commonly use these lenses for vision correction in patients.
What are the FDA-cleared indications?
The lenses are indicated for daily wear to correct myopia or hyperopia and should be discarded after each use.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.